March 20, 2024

MSD Animal Health receives positive CVMP opinion for Nobilis Multriva vaccine for use in chickens

MSD Animal Health, a division of Merck & Co, announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for its Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS vaccine.

The vaccine is to be administered intramuscularly in chickens from eight weeks of age, to protect against diseases caused by avian metapneumovirus also known as Turkey Rhinotracheitis (RT) virus, Infectious Bronchitis (IB) virus, Newcastle Disease (ND) virus, Infectious Bursal disease or Gumboro (G) virus, Reovirus (REO) and Egg Drop Syndrome (EDS) virus.

If the European Commission (EC) adopts this this recommendation, this would be the first vaccine of the Nobilis Multriva platform, an innovative, upgraded product range engineered with the needs of today's layers and breeders in mind.

"MSD Animal Health has been committed to bringing innovations to our customers that protect against the most important viral poultry pathogens for laying and breeding chickens," said Maxim Nakhodko, Global Poultry Business Unit Lead, MSD Animal Health.

"With today's positive opinion, the Nobilis Multriva™ RT+IBm+ND+Gm+REOm+EDS vaccine is one step closer to becoming the first 9-valent inactivated viral vaccine in Europe."

Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS combines proven protection with a convenient small dose volume of 0.3 ml allowing a new 2000 dose presentation, which produces less waste, reduces use of refrigerator space, and optimises the vaccination process.

Based on the CVMP's recommendation, the EC is expected to issue a decision for marketing authorisation in the European Union (EU) during the second quarter of 2024.

-      MSD Animal Health